English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
About ICMLF
Patient Groups: Spread the News
Patient Groups: Spread the News
Patient groups are uniquely placed to challenge fears and misperceptions that hamper prevention and contribute to late diagnoses, poor treatment and the social isolation of patients. Acting locally but using the Internet they are now campaigning globally. A recent article in "Cancerworld" also features the activities of The Max Foundation. See the article here.
Michele Baccarani
- Born in Bologna 16.08.1942
- M.D. degree 1966, University of Bologna
- Postgraduate degree in Hematology, 1969, University of Modena
- Research fellow, Rigshospitalet, University of Copenhagen, 1970
- Fellow, resident and senior resident at the Institute of Hematology "L. and A. Seràgnoli", S. Orsola University Hospital, Bologna, 1971-1980
- Professor of Cancer Chemotherapy, University of Chieti, 1980
- Professor of Hematology, University of Trieste, 1981-1986
- Professor of Hematology, University of Udine, from 1987 to 2000
- "Head, Division of Hematology and Bone Marrow Transplantation, Udine University Hospital, from 1989 to 2000
- Professor of Hematology, University of Bologna, from 2000
- Head, Institute of Hematology and Medical Oncology "L. and A. Seràgnoli", S.Orsola University Hospital, Bologna, from 2000 to 2007, and Department of Hematology and Oncology "L. and A. Seràgnoli" from 2008 .
- President, Italian Society of Experimental Hematology, 1994-1995
- President, Italian Society of Hematology, 2002-2003
- Chairman, GIMEMA CML Working Party (formerly Italian Coop. Study Group on Chronic Myeloid Leukemia), from 1989
- Member, Working Package 4 Chronic Myeloid Leukemia, European LeukemiaNet
- Vice-Dean, Faculty of Medicine and Surgery, University of Bologna, from 2001 to 2007
- Clinical interest: chronic myeloid leukemia, acute leukemia, chemotherapy, stem cell transplantation
- Research interest: cell kinetics, stem cells, multidrug resistance, molecular pathogenesis of leukemia
Oncology Times: International Foundation Launched for CML
Oncology Times: International Foundation Launched for CML
On 25 February 2010, the Oncology Times reported about the launch of the International CML Foundation (25 February 2010, Volume 32, Issue 4, pp 24-26, doi: 10.1097/01.COT.0000368857.22447.27). See the full text article here.
October is CML Awareness Month
October is CML Awareness Month
On October 1st, The Max Foundation opens a global awareness campaign to support survivors around the world by uniting people everywhere in the fight against cancer. The campaign aims at reducing the feelings of isolation of people facing cancer in developing countries and elsewhere.
Andrey Zaritskey
Andrey Zaritskey
Saint-Petersburg, Russia
Andrey Zaritskey is Professor of hematology, Director of Institute of Oncohematology of Federal center of Heart, Blood and Endocrinology and lecture of Saint-Petersburg Pavlov state Medical University. He was graduated and post-graduated in Saint-Petersburg Pavlov State Medical University during 1967-1978 years. He has published more than 197 articles/abstracts in national and international journals. His scientific interest is the study of chronic myeloid leukemia and chronic lymphoproliferative neoplasms (chronic lymphocytic leukemia and Non-Hodgkin lymphomas), mesenchymal cell-haematopoietic cell interactions. He has been participating in nilotinib, dasatinib and bosutinib phase II and III international studies. He is one of the leaders in chronic myeloid and lymphatic leukemia in Russia, and deputy-chair of the scientific board of Russian Experts in chronic
myeloid leukemia.
Stem Cell Transplantation
Hematopoetic Stem Cell Transplantation in CML
Few examples in clinical medicine demonstrate such a fascinating interaction as chronic myeloid leukemia (CML) and hematopoietic stem cell transplantation (HSCT). CML did provide first proof of principle that an incurable disease was amenable to successful treatment, that immune mediated mechanism could control a malignancy and that the risk of HSCT could be quantified by a few key factors. HSCT was nearly abandoned at the introduction of targeted therapy with imatinib. Today, it has a clear position and exemplifies the modern risk adapted approach.
